OmniAb, Inc.
OABI$3.08
+$0.84 (37.50%)+37.50%
ClosedLoading chart...
IndexN/A
Market Cap0.37B
Enterprise Value0.21B
Income$-0.02B
Sales$0.00B
EmployeesN/A
P/E-6.70
P/S11.26
P/B0.79
P/C-5.68
EV/EBITDA-4.60
EV/SalesN/A
EPS (ttm)-0.46
EarningsN/A
Gross Margin-18.17%
Oper. Margin-383.15%
Profit Margin-347.04%
Volume2.46M
Shs Outstand0.12B
Change37.50%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $26.39M | $34.16M | $59.08M | $34.75M | $23.27M | $18.32M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $26.39M | $34.16M | $59.08M | $34.75M | $23.27M | $18.32M |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | $100.89M | $103.58M | $85.72M | $70.36M | $48.89M | $31.34M |
| Operating Income | $-74.50M | $-69.42M | $-26.65M | $-35.61M | $-25.62M | $-13.03M |
| Operating Margin | -282.30% | -203.19% | -45.11% | -102.48% | -110.12% | -71.12% |
| Net Income | $-62.03M | $-50.62M | $-22.33M | $-27.04M | $-17.56M | $-13.59M |
| Net Margin | -235.05% | -148.16% | -37.80% | -77.82% | -75.46% | -74.18% |
| EPS (Basic) | $-0.61 | $-0.51 | $-0.26 | $-0.24 | $-0.15 | $-0.12 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $325.56M | $375.23M | $421.21M | $304.46M | $295.38M | $262.32M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $37.94M | $60.64M | $79.84M | $70.16M | $59.84M | $44.13M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $287.62M | $314.58M | $341.37M | $234.31M | $235.54M | $218.19M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $287.62M | $314.58M | $341.37M | $234.31M | $235.54M | $218.19M |
| Total Liabilities & Stockholders Equity | $325.56M | $375.23M | $421.21M | $304.46M | $295.38M | $262.32M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-62.03M | $-50.62M | $-22.33M | $-27.04M | $-17.56M | $-13.59M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-39.66M | $2.35M | $-3.59M | $-5.67M | $3.62M | $-5.20M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcriptseekingalpha.com OmniAb Q2 Earnings Call Highlightsmarketbeat.com OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimateszacks.com OmniAb Reports Second Quarter 2026 Financial Results and Business Highlightsbusinesswire.com VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAbglobenewswire.com OmniAb to Report Second Quarter 2026 Financial Results on August 6businesswire.com OmniAb Names Amechi Nwachuku Chief Operating Officergurufocus.com OmniAb Names Amechi Nwachuku Chief Operating Officerbusinesswire.com
Show 12 more stories
OmniAb Q1 Earnings Call Highlightsmarketbeat.com OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimateszacks.com OmniAb Reports First Quarter 2026 Financial Results and Business Highlightsbusinesswire.com OmniAb to Participate in Three Upcoming Investor Conferencesbusinesswire.com OmniAb to Report First Quarter 2026 Financial Results on May 7businesswire.com Matthew Foehr Sells 19,244 Shares of OmniAb (NASDAQ:OABI) Stockdefenseworld.net OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcriptseekingalpha.com OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimateszacks.com OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlightsbusinesswire.com OmniAb (OABI) Projected to Post Earnings on Wednesdaydefenseworld.net OmniAb to Report Fourth Quarter 2025 Financial Results on March 4businesswire.com OmniAb, Inc. (OABI) Discusses Launch and Scientific Overview of OmniUltra Technology Platform Transcriptseekingalpha.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Discover more
You may be interested in